(DVA) DaVita HealthCare Partners - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23918K1088

DVA: Dialysis, Labs, Research, Software, Care, Services, Management

DaVita Inc. (NYSE:DVA) is a leading provider of kidney dialysis services for patients with chronic kidney failure in the United States. The company operates a vast network of outpatient dialysis centers, offering a range of services including hemodialysis, peritoneal dialysis, and home-based dialysis care. Beyond its core dialysis operations, DaVita provides clinical laboratory services, disease management programs, and integrated care services for patients with end-stage renal disease (ESRD). Its comprehensive offerings extend to acute inpatient dialysis, physician services, and transplant software solutions.

DaVitas business model is heavily integrated, allowing it to manage the full spectrum of kidney care. The company partners with nephrologists and healthcare providers to deliver coordinated care, reducing hospitalizations and improving patient outcomes. Its scale and operational efficiency make it one of the largest dialysis providers in the U.S., with a significant market share. DaVita also engages in clinical research initiatives, contributing to advancements in kidney disease treatment and management.

From a financial perspective, DaVita Inc. operates with a market capitalization of approximately $14.5 billion, reflecting its established position in the healthcare services sector. The companys valuation metrics, such as a P/E ratio of 19.08 and a forward P/E of 15.29, indicate a premium valuation relative to its earnings. The P/S ratio of 1.15 highlights its revenue generation capabilities. These metrics are important for investors assessing the companys growth prospects and profitability in the dialysis and kidney care space.

Headquartered in Denver, Colorado, DaVita Inc. was founded in 1994 and has since grown into a critical player in the healthcare services industry. Its focus on patient care, operational excellence, and innovation positions it as a key participant in the evolving landscape of kidney disease management. For investors and fund managers, DaVita represents a significant entity in the healthcare sector, with a strong track record of delivering essential services to patients with chronic kidney failure.

Web URL: https://www.davita.com

Ticker Symbol: DVA Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Health Care Services Market Cap or AUM: 14523.17M USD P/E: 19.08 P/E Forward: 15.29 P/B: 37.56 P/S: 1.15

Additional Sources for DVA Stock

DVA Stock Overview

Market Cap in USD 11,290m
Sector Healthcare
Industry Medical Care Facilities
GiC Sub-Industry Health Care Services
IPO / Inception 1995-10-31

DVA Stock Ratings

Growth 5y 57.6%
Fundamental 62.6%
Dividend 0.0%
Rel. Strength Industry 4.55
Analysts 3.1/5
Fair Price Momentum 140.60 USD
Fair Price DCF 424.69 USD

DVA Dividends

No Dividends Paid

DVA Growth Ratios

Growth Correlation 3m -26.8%
Growth Correlation 12m 72.5%
Growth Correlation 5y 46.9%
CAGR 5y 14.84%
CAGR/Max DD 5y 0.29
Sharpe Ratio 12m 1.37
Alpha -4.39
Beta 0.87
Volatility 37.64%
Current Volume 759.4k
Average Volume 20d 1210k
What is the price of DVA stocks?
As of March 15, 2025, the stock is trading at USD 143.45 with a total of 759,408 shares traded.
Over the past week, the price has changed by -2.43%, over one month by -8.87%, over three months by -4.74% and over the past year by +5.48%.
Is DaVita HealthCare Partners a good stock to buy?
Yes, based on ValueRay Fundamental Analyses, DaVita HealthCare Partners (NYSE:DVA) is currently (March 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 62.58 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DVA as of March 2025 is 140.60. This means that DVA is currently overvalued and has a potential downside of -1.99%.
Is DVA a buy, sell or hold?
DaVita HealthCare Partners has received a consensus analysts rating of 3.10. Therefor, it is recommend to hold DVA.
  • Strong Buy: 1
  • Buy: 0
  • Hold: 8
  • Sell: 1
  • Strong Sell: 0
What are the forecast for DVA stock price target?
According to ValueRays Forecast Model, DVA DaVita HealthCare Partners will be worth about 151.9 in March 2026. The stock is currently trading at 143.45. This means that the stock has a potential upside of +5.86%.
Issuer Forecast Upside
Wallstreet Target Price 163.3 13.8%
Analysts Target Price 161.6 12.6%
ValueRay Target Price 151.9 5.9%